AR092993A1 - Laquinimod para reducir el daño talamico en la esclerosis multiple - Google Patents
Laquinimod para reducir el daño talamico en la esclerosis multipleInfo
- Publication number
- AR092993A1 AR092993A1 ARP130103705A ARP130103705A AR092993A1 AR 092993 A1 AR092993 A1 AR 092993A1 AR P130103705 A ARP130103705 A AR P130103705A AR P130103705 A ARP130103705 A AR P130103705A AR 092993 A1 AR092993 A1 AR 092993A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- subject
- multiple sclerosis
- damage
- affected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Abstract
Método para inhibir o reducir el daño talámico en un sujeto que comprende administrarle al sujeto una cantidad de laquinimod, en donde el sujeto es un paciente humano afectado por una forma de esclerosis múltiple o que presenta un síndrome clínicamente aislado al que se le ha determinado que tiene daño talámico en condiciones basales, un sujeto afectado por una enfermedad o trastorno diferente de una forma de esclerosis múltiple o un síndrome clínicamente aislado, o un sujeto que no está afectado por una forma de esclerosis múltiple ni presenta un síndrome clínicamente aislado, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Métodos para inhibir o reducir el tremor o espasticidad en un sujeto afectado por tremor o espasticidad, que comprende administrarle al sujeto una cantidad de laquinimod, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Reivindicación 51: Laquinimod caracterizado porque es para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales. Reivindicación 52: Una composición farmacéutica caracterizada porque comprende una cantidad de laquinimod para usar en la inhibición o reducción del daño talámico en un paciente humano al que se le ha determinado que tiene daño talámico en condiciones basales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092993A1 true AR092993A1 (es) | 2015-05-13 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103705A AR092993A1 (es) | 2012-10-12 | 2013-10-11 | Laquinimod para reducir el daño talamico en la esclerosis multiple |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (es) |
| EP (1) | EP2961406A4 (es) |
| JP (1) | JP2015533163A (es) |
| KR (1) | KR20150080509A (es) |
| CN (1) | CN105263325A (es) |
| AR (1) | AR092993A1 (es) |
| AU (2) | AU2013329348A1 (es) |
| BR (1) | BR112015007782A2 (es) |
| CA (1) | CA2884272A1 (es) |
| CL (2) | CL2015000732A1 (es) |
| EA (1) | EA201590726A1 (es) |
| HK (1) | HK1218865A1 (es) |
| IL (1) | IL237745A0 (es) |
| MX (1) | MX2015004564A (es) |
| PE (1) | PE20151435A1 (es) |
| SG (1) | SG11201501874TA (es) |
| TW (1) | TW201420101A (es) |
| WO (1) | WO2014058979A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140138694A (ko) | 2012-02-03 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| CA2933380A1 (en) * | 2013-12-20 | 2015-06-25 | Esther Lukasiewicz Hagai | Use of laquinimod to delay huntington's disease progression |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| WO2018053040A1 (en) * | 2016-09-13 | 2018-03-22 | Intekrin Therapeutics, Inc. | Treatment of multiple sclerosis with chs-131 |
| EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060276393A1 (en) * | 2005-01-13 | 2006-12-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| CA2657716A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Cholanic acid amides |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| AU2010260455A1 (en) * | 2009-06-19 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| JP5859438B2 (ja) * | 2009-08-10 | 2016-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いたｂｄｎｆ関連疾患の治療 |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| BR112013014061A2 (pt) * | 2010-12-07 | 2016-09-13 | Teva Pharma | uso de laquinimod para redução da fadiga, melhorando o estado fundicional e melhorando a qualidade de vida nos pacientes com esclerose múltipla |
| CA2830027C (en) * | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| EP2766020A4 (en) * | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en active Application Filing
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Application Discontinuation
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-15 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL237745A0 (en) | 2015-05-31 |
| US20160296511A1 (en) | 2016-10-13 |
| WO2014058979A8 (en) | 2015-04-16 |
| CL2015000732A1 (es) | 2015-08-07 |
| TW201420101A (zh) | 2014-06-01 |
| AU2017203896A1 (en) | 2017-06-29 |
| WO2014058979A3 (en) | 2015-08-20 |
| CN105263325A8 (zh) | 2017-07-14 |
| EA201590726A1 (ru) | 2015-10-30 |
| EP2961406A2 (en) | 2016-01-06 |
| BR112015007782A2 (pt) | 2017-07-04 |
| CN105263325A (zh) | 2016-01-20 |
| EP2961406A4 (en) | 2017-01-04 |
| AU2013329348A1 (en) | 2015-05-28 |
| MX2015004564A (es) | 2015-07-21 |
| KR20150080509A (ko) | 2015-07-09 |
| PE20151435A1 (es) | 2015-10-15 |
| US20140107154A1 (en) | 2014-04-17 |
| WO2014058979A2 (en) | 2014-04-17 |
| JP2015533163A (ja) | 2015-11-19 |
| SG11201501874TA (en) | 2015-05-28 |
| CL2016002873A1 (es) | 2017-04-17 |
| HK1218865A1 (zh) | 2017-03-17 |
| CA2884272A1 (en) | 2014-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015533163A5 (es) | ||
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| JP2013520447A5 (es) | ||
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| BR112016016098A2 (pt) | Compostos orgânicos | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| BR112015007095A8 (pt) | derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados | |
| BR112013025368A8 (pt) | Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame | |
| UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple | |
| WO2013049280A3 (en) | Sphingosine analogs, compositions, and methods related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |